Fennec COO Adrian Haigh departs

Fennec Pharmaceuticals announced that Adrian Haigh has departed from his position as Fennec’s COO as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as COO. “We are grateful to Adrian for joining Fennec’s leadership team at such a critical point in the commercial evolution of the Company last year. His significant experience in evaluating business development opportunities and preparing global commercial operations proved successful, as evidenced by the exclusive licensing agreement announcement, which we executed earlier this year with Norgine, to commercialize PEDMARQSI in Europe, Australia, and New Zealand. The Company is actively searching for a U.S.-based leader,” said Rosty Raykov, CEO.